setipiprant
Small moleculeexperimental
Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. — Wikipedia
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01225315)
Timeline
Indications
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
PTGDR2 antagonist
Indication: Seasonal allergic rhinitis, asthma
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2- Mol. weight
- 402.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSetipiprant ↗
- ChEMBLCHEMBL2386081 ↗
Also known as
- 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1h-pyrido(4,3-b)indol-5(2h)-yl)acetic acid
- act-129968
- act-129968
- act-129968
- act-129968
- kyth-105
- kyth-105
- setipiprant
- setipiprant
- setipiprant
- setipiprant
- setipiprant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02781311 | Phase 2 | Jun 29, 2016 | Allergan |
| NCT01484119 | Phase 3 | Dec 1, 2011 | Actelion |
| NCT02381496 | Phase 1 | Dec 1, 2011 | Actelion |
| NCT01877629 | Phase 1 | Jun 1, 2011 | Actelion |
| NCT01241214 | Phase 2 | Nov 1, 2010 | Actelion |
| NCT01225315 | Phase 2 | Oct 1, 2010 | Actelion |
Showing 6 of 6 trials
Page 1 / 1